Similarly, other TKIs like erlotinib exhibit >70% response rates in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) activating mutations [5–7]. Here, EGFR is linked to non-small cell lung carcinoma.